Still believe 2012 numbers will exceed our expectations. Just know it is a very rare situation when small pharma has strong cash, partners, and an excellent drug pipeline also. June should be a good month for increased fund buying and price action.
All else being equal from other forecast they put out for 2012, loss for year should be about $10M and they should be cash positive for the year. Impressive given the R&D spending this year and the $10M cash payment in Feb to the former Astex shareholders.